In March 2007 Glenmark Pharmaceuticals completed the acquisition of Medicamenta a.s., a Czech-based pharmaceutical company. This marked the beginning of Glenmark’s presence in Central Eastern Europe, one of the most promising regions in the world for branded formulations. This was the first operational subsidiary in Europe with presence in both countries i.e. Czech Republic and Slovakia.
In July 2008, Glenmark made its entry into Poland by acquiring a portfolio of seven branded products from Actavis. The acquisition of this product portfolio went well with Glenmark’s overall strategy for increasing revenue and accelerating growth in a key strategic market like Poland.
Earlier in that same year 2008, Glenmark Pharmaceuticals began operations in Romania. The Romanian company is already marketing a number of CNS and cardiovascular products including the specialty products ‘Aflen’ and ‘Eneas’.
The total number of products sold in this region are over 25.
|
Therapy Segments |
|
| The Key therapy segments for this region are
|
Central Nervous System(CNS) |
Cardiovascular (CV) |
Metabolic & |
Respiratory |
|
|
Key Brands |
|
Flagship brands |
Ataralgin |
Cital |
Lamotrix |
Aflen |
| |
Other Top performing products/brands are |
Topimark & Ataralgin in Czech Republic and Slovakia. |
Cital and Lamotrix in Poland. |
Aflen and Eneas in Romania. |
ATARALGIN – Czech Republic |
CITAL, LAMOTRIX – Poland |
|
|
Acquisitions |
|
Czech & Slovakia |
In March 2007, Glenmark concluded a deal to acquire majority shareholding in Medicamenta a.s, a Czech based pharmaceutical company giving Glenmark its first commercial foothold into this strategically important market of Europe. Through the acquisition, Glenmark also got access to Medicamenta’s manufacturing facility in Vysoke Myto in the Czech Republic |
| |
Poland |
In July 2008, Glenmark announced that its European organisation, acting through its Czech subsidiary Medicamenta, signed agreements with Actavis, the international generic pharmaceutical company from Iceland, and Biovena (an affiliate of Actavis in Poland) to acquire seven pharmaceutical brands. The acquisition of the products provided Glenmark its first access to the growing Polish market, the largest pharmaceutical market in Central & East Europe. |
|